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CLINICAL RELEVANCE 
 
Scientific rationale for the study: Autogenous subepithelial connective tissue grafts 
(SCTGs) are the gold standard to augment soft tissue volume at implant sites. In order 
to reduce the morbidity, research activities have focused on soft tissue substitutes. A 
recently developed three-dimensionally stable collagen matrix (VCMX) demonstrated 
favorable biological properties in preclinical studies. This clinical study aimed to confirm 
the effectiveness and safety of VCMX in comparison to SCTG. 
Principal findings: Soft tissue augmentation was a safe procedure increasing the soft 
tissue thickness up to 1.6 mm without relevant differences between VCMX and SCTG. 
Practical implications: VCMX might replace SCTGs for the augmentation of soft tissue 
volume at implant sites in the future. 
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ABSTRACT 
 
Aim: To test whether or not the use of a collagen matrix (VCMX) results in short-term 
soft tissue volume increase at implant sites non-inferior to an autogenous subepithelial 
connective tissue graft (SCTG) and, to evaluate safety and tissue integration of VCMX 
and SCTG. 
Methods: In 20 patients with a volume deficiency at single-tooth implant sites, soft 
tissue volume augmentation was performed randomly allocating VCMX or SCTG. Soft 
tissue thickness, patient-reported outcome measures (PROMs), and safety were 
assessed up to 90 days (FU-90). At FU-90 (abutment connection), tissue samples were 
obtained for histological analysis. Descriptive analysis was computed for both groups. 
Nonparametric tests were applied to test non-inferiority for the gain in soft tissue 
thickness at the occlusal site. 
Results: Median soft tissue thickness increased between BL and FU-90 by 1.8mm 
(Q1:0.5;Q3:2.0) (VCMX) (p=0.018) and 0.5mm (-1.0;2.0) (SCTG) (p=0.0.395) 
(occlusal) and by 1.0mm (0.5;2.0) (VCMX) (p=0.074) and 1.5mm (-2.0;2.0) (SCTG) 
(p=0.563) (buccal). Non-inferiority with a non-inferiority margin of 1mm could be 
demonstrated (p=0.020), the difference of the two group medians (1.3mm) for occlusal 
sites indicated no relevant, but not significant superiority of VCMX vs. SCTG  (primary 
endpoint). Pain medication consumption and pain perceived were non-significantly 
higher in group SCTG up to day 3. Median physical pain (OHIP-14) at day 7 was 100% 
higher for SCTG than for VCMX. The histological analysis revealed well-integrated grafts. 
Conclusions: Soft tissue augmentation at implant sites resulted in a similar or higher 
soft tissue volume increase after 90 days for VCMX vs. SCTG. PROMs did not reveal 
relevant differences between the two groups. 
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INTRODUCTION 
Immediately following tooth extraction biological processes are initiated, which can lead 
to bone resorption and result in localized alveolar ridge defects (Van der Weijden et al., 
2009, Araujo and Lindhe, 2009). A number of surgical techniques were proposed to 
correct localized alveolar defects (Prato et al., 2004). Depending on the dimension and 
the location of the site and depending on the restorative treatment planning the use of 
bone augmentation (Aghaloo and Moy, 2007, Jensen and Terheyden, 2009, Milinkovic 
and Cordaro, 2014, Chiapasco et al., 2009) as well as soft tissue augmentation (Eghbali 
et al., 2014, De Bruyckere et al., 2015, Esposito et al., 2012) or a combination of both 
procedures (Schneider et al., 2011, Cosyn et al., 2015) have been reported. 
According to two recent systematic reviews, autogenous subepithelial connective tissue 
grafts (SCTGs) are considered to be the gold standard to augment soft tissue volume at 
implant sites and in partially edentulous patients (Thoma et al., 2009, Thoma et al., 
2014a). Limitations and disadvantages, however, are associated with the use of 
autogenous tissue. These typically include i) the height, length and thickness of the 
donor tissue vary with the different anatomic dimensions of the palatal vault (Benninger 
et al., 2012), ii) length and thickness are limited by anatomical factors such as a thick 
alveolar process, exostosis and the palatine nerves and blood vessels (Kim et al., 2014, 
Yu et al., 2014, Fu et al., 2011), iii) patients often complain about pain and numbness 
especially in the donor site for several weeks after the surgery (Zucchelli et al., 2010, 
Griffin et al., 2006, Cairo et al., 2012, Soileau and Brannon, 2006). In order to reduce 
the morbidity due to the harvesting procedures and overcome the above-mentioned 
issues of autogenous grafts, research activities have focused on the development of soft 
tissue substitutes of various origins and for a number of clinical indications (Zuhr et al., 
2014, Vignoletti et al., 2014). For the purpose of soft tissue volume augmentation, a 
suitable device needs to fulfill two main criteria: i) volume stability over time, ii) 
favorable biological behavior allowing modeling and remodeling processes. Most soft 
tissue substitutes brought on the market in recent years fulfilled the latter criteria. 
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Effective volume increase and volume stability over time has not been shown yet. 
Recently, a three-dimensionally stable collagen matrix was developed. This matrix 
demonstrated i) favorable mechanical properties and biological attributes promoting the 
ingrowth of human fibroblasts (Mathes et al., 2010), ii) favorable tissue integration and 
promotion of angiogenesis (Thoma et al., 2012b) and iii) non-inferiority compared to the 
gold standard in terms of two- and three-dimensional volume increase in a preclinical 
model (Thoma et al., 2010, Thoma et al., 2011). Still, data from in vitro and 
experimental preclinical studies may be difficult to transfer into the clinic. Therefore, the 
aim of the present randomized controlled clinical trial was i) to test whether or not the 
use of a collagen matrix (VCMX) results in a soft tissue volume increase at implant sites 
non-inferior to a subepithelial connective tissue graft (SCTG), ii) to evaluate safety and 
tissue integration of VCMX and SCTG. 
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MATERIALS AND METHODS 
Study design 
This study was designed as a randomized controlled clinical trial and performed in 
accordance with the ISO Standard 14155:2011, Clinical Investigation of medical devices 
for human patients with the appendices VIII and X of the Medical Device Directive 
93/42/EEC and with the Declaration of Helsinki, 2004. Upon approval by the local ethics 
committee (KEK-ZH-Nr 2011-0408), patients in need of soft tissue volume increase at 
single-tooth implant sites were consecutively recruited, informed and screened for 
inclusion. The following inclusion criteria were applied: 
Inclusion criteria: 
1. Implant placement at least 6 weeks and maximum 6 months prior enrolment 
2. Necessity of soft tissue augmentation in a single tooth gap 
3. 2 teeth adjacent at each side of the defect with a mean BOP of < 30% 
4. Basic periodontal examination (BPE <2) 
5. 18 years or older 
6. Ability to comply with the study-related procedures such as exercising 
good oral hygiene and attending all follow-up examinations 
7. Ability to fully understand the nature of the proposed surgery and ability to sign the 
informed consent form 
Exclusion criteria: 
1. Heavy smoker (> 10 cigarettes per day) 
2. Probing depth greater than 4 mm 
3. Insulin-dependent diabetes 
4. General contraindications for dental and/or surgical treatment 
5. History of malignancy, radiotherapy, or chemotherapy for malignancy within the past 
five years 
6. Women of child bearing age, not using a standard accepted method for contraception 
7. Pregnancy or breast feeding 
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8. Previous and concurrent medication affecting mucosal healing in general (e.g. 
steroids, large doses of anti-inflammatory drugs) 
9. Disease affecting connective tissue metabolism (e.g. collagenases) 
10. Allergy to collagen 
 
Clinical procedures 
Screening 
Following inclusion in the study, patients were scheduled for a screening visit. At this 
time-point a number of clinical measurements were performed including basic 
periodontal parameters and impression taking of the augmentation site (for details see 
below and Figures 1 and 2A). 
Soft tissue augmentation surgery 
At the day of surgery, patients rinsed with 0.2% chlorhexidine solution (Hibitan, Astra-
Zeneca) for 60 seconds and were then premedicated with 500mg mefenaminacid 
(Ponstan 500, Parke-Davis) and 1.5g of amoxicilline (Amoxicilline, Sandoz). Following 
local anesthesia, sulcular incisions were made around the neighbouring teeth and a 
straight incision from the lingual/palatal line angle of the distal tooth to the 
lingual/palatal line angle of the mesial tooth. A full thickness flap was elevated on top of 
the ridge crest between the two neighboring teeth. At the border between the ridge crest 
and the buccal aspect, a split thickness flap was prepared by a sharp dissection using a 
blade (Figure 2B). Thereby, the periosteum was not elevated on the buccal aspect. 
Subsequently, the split thickness flap on the buccal side was extended to prepare a 
pouch. The dimension of the buccal pouch exceeded the expected size of the transplant. 
In addition, periosteal releasing incisions were made on the buccal side to allow for a 
tension-free wound closure. At this time-point a sealed envelope containing the 
randomly assigned treatment modality was opened. 
Treatment modalities: 
- cross-linked volume-stable collagen matrix (VCMX) (test) 
- autogenous subepithelial connective tissue graft (SCTG) (control) 
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In group VCMX, the matrix was shaped to match the desired size in the recipient bed 
(original dimension: 8mm x 8mm x 5mm). In group SCTG, an autogenous connective 
tissue graft was harvested using a single incision technique. The VCMX/SCTG was then 
positioned in the pouch under the elevated buccal flap (Figure 2C). A horizontal single 
suture was made to immobilize the VCMX/SCTG, connecting it to the lingual flap (Gore 
Tex 5-0, W.L.Gore & Associates, Inc). One horizontal mattress suture (Gore Tex 5-0, 
W.L.Gore & Associates, Inc) was placed over the buccal prominence created by the 
volume gain through the applied VCMX/SCTG in order to stabilize the augmented area 
and to approach the wound margins. Finally, single interrupted sutures (3-5) closed the 
wound bed (Figure 2D). In group SCTG, the palatal donor site was closed using a 
horizontal cross-section suture. The overall surgical time to perform the soft tissue 
augmentation procedures was calculated in minutes. Patients received prescriptions for 
analgesic and anti-inflammatory medications for three days (Ponstan®, Parke-Davis) 
and were instructed to rinse with a 0.2% solution of chlorhexidine (Hibitan, Astra-
Zeneca) twice a day for 10 days. Additionally, the patients were instructed to take 2.25 
g amoxicilline (Amoxicilline, Sandoz) per day for 7 days. Any temporary removable 
partial denture was checked and adapted if necessary to avoid trauma to the surgical 
area.  
Follow-up examinations (Suture Removal (SR); FU-30; FU-90) 
Sutures were removed 7-10 days after the surgery and teeth were professionally cleaned 
with a mild abrasive prophylaxis paste (suture removal = SR). In addition, the soft 
tissue healing was assessed at the target and donor site (if applicable) (Figure 2E). Any 
kind of dehiscence or swelling was recorded at target and donor site. In addition, 
patient-reported outcome measures (PROMs) were assessed (see below and Figure 1). 
At 30 (Figure 2F) and 90 days post surgery (FU-30; FU-90), periodontal parameters, the 
soft tissue healing and PROMs were recorded. In addition, at FU-90, a minimally invasive 
abutment connection was performed using a u-shaped incision design (Figure 2G). The 
cover screw of the implant was removed and a small biopsy (roughly 2x2mm) including 
soft tissue on top of the implant harvested. The small flap was placed underneath the 
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buccal pouch and a healing abutment connected to the implant (Figure 2H). Similar to 
FU-30, PROMs were assessed. The performance of the treatment per se was judged 
subjectively at FU-90 by the clinicians as being successful (gain in volume) or 
unsuccessful (need for an additional soft tissue grafting procedure). 
 
Outcome measures 
Assessment of soft tissue thickness at BL (=prior to surgery), at 30 days, at 90 days 
The primary efficacy outcome was the gain in mucosal soft tissue thickness (measured 
at the occlusal aspect) at day 90 compared to day 0 (baseline value) measured by 
transmucosal probing.  
In order to assess the changes in soft tissue thickness at the target site, an alginate 
impression was taken at screening and an individualized stent with three standardized 
openings (occlusal, buccal, apical) fabricated by means of CAD/CAM technology 
according to a previously published protocol (Figure 3A) (Thoma et al., 2012a). 
Transmucosal probing for mucosal thickness was performed with an endodontic 
instrument (RS STER K-File 31/15, Dentsply Maillefer). The stent served as a guide for 
reproducible measurements of the soft tissue thickness. After placing the individualized 
stent, the soft tissue thickness was measured by introducing the endodontic instrument 
in the openings and penetrating the mucosa to the bone (Figure 3B). With an additional 
measurement the tip of the endodontic instrument stopped on top of the mucosa. The 
difference between the two measurements represented the soft tissue thickness.  
Assessment of periodontal status 
Standard clinical and periodontal measurements were performed at BL, at 30 days and 
at 90 days and included: the basic periodontal examination (BPE) in all sextants, plaque 
index (PlI) at six sites around the neighboring teeth according to Silness-Löe, the width 
of keratinized tissue (KT) at the buccal side of the two neighboring teeth, bleeding on 
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probing (BOP) as present or not at the two neighboring teeth, and periodontal probing 
depth (PPD), clinical attachment level (CAL) and recession depth (RC) at six sites 
around the two neighboring teeth. 
Patient-reported outcome measures (PROMs) 
PROMs were assessed calculating the overall consumption of analgesics (Ponstan 500, 
Parke-Davis) during the entire study period using self-reported questionnaires handed-
out to the patients at each visit and being collected at the follow-up visit. Pain perceived 
by patients between the follow-up visits was assessed by documenting the intake of 
analgesics / anti-inflammatory medication (Ponstan 500, Parke-Davis). During the first 
7-10 days after surgery, overall pain was daily assessed by the patients using a 
questionnaire (visual analog scale = VAS), thereafter one of the investigators (MZ) 
recorded pain at FU-30 and FU-90 using the same VAS. In addition, an oral health 
impact profile questionnaire (OHIP-G14) was handed out to patients and filled out at SC 
(screening, baseline=BL), SR and FU-90.  
Safety evaluations 
Any adverse event and complication as well as wound closure, the presence of swelling 
and concomitant medication were recorded during the entire study period. 
Histological preparation and assessment 
Obtained biopsies were fixed, decalcified, dehydrated in alcohol solutions of increasing 
concentration, cleared in isoparaffin H and embedded in paraffin. Embedded samples 
were cut at 5 µm using a microtome. One section per block was prepared and stained 
with Van Gieson-Elastica to study the remaining amount of the VCMX and the newly 
formed connective tissue (group VCMX), whereas in group SCTG, the overall amount of 
connective tissue was calculated. All histological sections were evaluated using a 
microscope for qualitative and semi-quantitative histological analysis. For 
histomorphometrical analysis, the digitized histological images were analyzed using an 
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image-processing program. The following parameters were assessed within a defined 
region of interest in the center of the biopsy: i) connective tissue, ii) remaining VCMX, 
iii) background. One masked experienced examiner performed all the measurements. 
 
Statistical analysis  
Mean, median, standard deviation and the range were used to describe the continuously 
scaled variables and counts and percentages for categorically scaled variables. 
Nonparametric statistical methods were applied. The differences of the medians 
between the treatment groups were evaluated with the Mann-Whitney and within a 
treatment group with the Wilcoxon signed rank test. 
 
The data were analyzed as intention-to-treat set (ITT: all randomized patients with 
post-baseline data) as well as per protocol analysis set (PP: ITT without major protocol 
violations). No relevant differences were found between the results in both analysis 
sets. The results for the primary objective are therefore presented as PP analysis set 
(ITT analysis is not generally conservative in non-inferiority trials). 
Descriptive statistics and simple comparisons are reported for the ITT analysis set. In 
order to demonstrate that the two treatment groups do not differ relevantly with respect 
to the medians of change in soft tissue thickness (ΔVCMX and ΔSCTM), a non-inferiority test 
was performed. This non-inferiority test was applied for results from the occlusal site as 
a primary endpoint at a 1-sided significance level of 2.5% with an equivalence margin of 
δ=-1mm based on nonparametric tests. The null hypothesis for the non-inferiority is 
defined for the occlusal site: H0: ΔVCMX−ΔSCTM≤−δ and the alternative hypothesis: Δ
VCMX−ΔSCTM>−δ. If the non-inferiority can be shown, then in a hierarchical way, one 
may test for superiority.  
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The sample size calculation yielded 10 patients per group (total 20 patients) by taking 
into account a standard deviation of 0.5 mm per group, 90% power, and a drop-out rate 
of 30% without correction for the non-normality of the data. 
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RESULTS 
Patient recruitment phase started in February 2012 and ended in February 2013. 
Twenty-one patients were screened and finally, a total of 20 patients entered the clinical 
trial having fulfilled all inclusion criteria. Ten patients (mean age 43.8 ± 13.2 years) 
were allocated to group VCMX (7 female, 3 male) and 10 patients (mean age 42.7 ± 
19.1 years) to group SCTG (6 female, 4 male). A detailed description on patient 
demographics and augmentation sites is displayed in Tables 1A and 1B. All 20 included 
patients were operated and subsequently completed the study. 
No relevant differences regarding baseline periodontal parameters were observed 
between the groups. 
The median surgery time for the two groups amounted to 39.0min (Q1:33.0;Q3:51.0) 
(VCMX) and 34.0min (Q1:27.0;Q3:45) (SCTG) (p=0.319).  
The clinicians considered the treatment to be successful in 9 out of 10 patients in both 
groups. In two patients (one in each group), clinically, no or only limited volume gain 
was observed and the therapies therefore considered being unsuccessful. 
Soft tissue thickness  
The median thickness of the mucosa at baseline was 3.5mm (2.5;4.9) (VCMX) and 
3.8mm (3.0;5.0) (SCTG) (p=0.442) at the occlusal site, buccally, the respective values 
were 3.0mm (1.5;3.0) (VCMX) and 4.0mm (3.5;4.5) (SCTG) (p=0.211), and apically 
2.0mm (1.0;3.0) (VCMX) and 3.0mm (2.5;3.5) (SCTG) (p=0.246). All data are given in 
Table 2A. 
The changes between BL and FU-30 revealed a median increase in mucosal thickness of 
1.0mm (0.0;2.0) (VCMX) (p=0.090) and 0.5mm (0.0;2.0) (SCTG) (p=0.156) at the 
occlusal site, of 1.0mm (1.0;3.0) (VCMX) (p=0.016) and 1.5mm (0.5;2.5) (SCTG) 
(p=0.086) buccally and by 2.5mm (1.0;4.0) (VCMX) (p=0.004) and 2.0mm (1.0;3.0) 
(SCTG) (p=0.141) apically. No statistically significant differences were found between 
VCMX and SCTG (p=0.987; p=0.953; p=0.481) for the changes between BL and FU-30. 
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The median thickness values at FU-30 [FU-90] were 4.0m (3.0;5.0) (VCMX) and 5.0mm 
(4.5;5.5); SCTG) (p=0.109) [4.25mm (3.5;6.0) (VCMX) and 4.0mm (4.0;6.5) (SCTG), 
p=0.613] at the occlusal site, buccally, the respective values were 4.5mm (4.0;5.0) 
(VCMX) and 5.8mm (4.5;7.0) (SCTG) (p=0.061) [4.0mm (3.5;4.5) (VCMX) and 5.3mm 
(4.5;5.5) (SCTG) p=0.136], and apically 4.8mm (4.0;5.0) (VCMX) and 5.0mm (3.5;7.0) 
(SCTG) (p=0.924) [2.5mm (2.0;4.5) (VCMX) and 5.0mm (4.0;7.0) (SCTG) p=0.081].  
In terms of primary endpoint, the overall median soft tissue thickness increased 
between BL and FU-90 by 1.8mm (0.5;2.0) (VCMX) (p=0.018) and 0.5mm (-1.0;2.0) 
SCTG) (p=0.395) at the occlusal site. Hereby, the difference between the treatment 
related gains (primary objective) was 0.6 mm (difference of the medians 1.25); non-
inferiority could be demonstrated (p=0.020). Superiority could not be shown. The two-
sided nonparametric 95% confidence interval of the differences of the primary endpoint 
between the two groups was (-0.5, 2.0).  
For all other sites, similar median increases were observed: 1.0mm (0.5;2.0) (VCMX) 
(p=0.074) and 1.5mm (-2.0;2.0) (SCTG) (p=0.563) buccally and 0.0mm (-0.5;1.5) 
(VCMX) (p=0.281) and 1.8mm (-0.5;3.3) (SCTG) (p=0.148) apically, respectively. No 
statistically significant differences were found between VCMX and SCTG (p=1.000; 
p=0.470). 
The median changes between FU-30 and FU-90 amounted to 0.3mm (-0.5;0.5) (VCMX) 
(p=0.730) and -0.5mm (-10;1.0) (SCTG) (p=0.803) at the occlusal site, to -0.5mm (-
0.5;0.5) (VCMX) (p=0.492) and -0.3mm (-1.0;0.8) (SCTG) (p=0.750) buccally and, to -
1.5mm (-3.0;0.0) (VCMX) (p=0.016) and 1.0mm (0.0;2.0) (SCTG) (p=0.398) apically. 
Statistically significant differences were found between VCMX and SCTG apically 
(p=0.015), but not at the occlusal (p=0.513) and buccal site (p=0.914). 
All data are displayed in Tables 2A and 2B. 
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Periodontal outcome measures 
These measurements included KM, PPD, CAL, BOP, PlI values. For the width of 
keratinized tissue, no significant differences were observed between the two groups at 
the mesial tooth (p=0.264) and the target site (p=0.624). However, at the distal 
neighboring tooth, the difference in KM was statistically significantly between VCMX and 
SCTG (-1.1mm; Q1:-2.0; Q3:0.1) (p=0.029). All other outcome measures did only show 
minimal differences between the two groups (data not shown). 
 
Patient-reported outcome measures (PROMs) 
VAS scores were calculated four hours after the surgery and then daily until suture 
removal, as well at FU-30 and FU-90. Figure 4A demonstrates a slightly higher VAS 
score for SCTG between day 1 and day 3 post surgery without being statistically 
significantly different at any time-point (p>0.05). This correlated with a slightly higher 
consumption of analgesics from the day of surgery until suture removal for SCTG (5 
tablets; Q1:2;Q3:7) compared to VCMX (3 tablets; Q1:1;Q3:6) (Figure 4B). Similar 
observations were made analyzing the OHIP-G14 questionnaire. Tables 3A and 3B show 
descriptive statistics for group differences for OHIP-14 subscores and total scores at 
baseline (BL), SR and FU-90 as well as for changes between SR and BL and between FU-
90 and SR. In addition, p-values resulting from Mann-Whitney-U-tests (absolute values) 
and Wilcoxon signed rank test (comparing changes) of between-treatment and within-
treatment differences were derived. All p values are above 0.10 and are therefore not 
reported in the tables. At suture removal, median overall scores for SCTG (5.0; Q1:3.0; 
Q3:11.0) were higher than for VCMX (3.0; Q1:0; Q3:6)) without reaching statistically 
significant differences (p=0.340). Median physical pain was 100% higher in group SCTG 
(3.0; Q1:1.0; Q3:3.0)) compared to group VCMX (1.5; Q1:0.0; Q3:2.0)) (p=0.113) at 
SR, thereby demonstrating a trend for VCMX to be associated with less morbidity. This 
was further underlined when analyzing the changes between baseline and SR. The 
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greatest differences between the groups (for changes between SR and BL) were found 
for physical pain (p=0.126) and social disability (p=0.187). 
Safety evaluations 
The status of the wound closure at the target site was assessed at day 7, 30 and 90 
days. At the day of suture removal, 67% in group VCMX and 90% in group SCTG 
demonstrated a complete wound closure. This difference was not statistically significant 
and demonstrated an ODDs ratio of 0.22 (95% confidence interval 0.018-2.674). In 5/10 
patients (VCMX) and 2/20 patients (SCTG) respectively, swelling was present at the 
same visit. At the two later follow-up time-points, all target sites were completely closed 
and no swelling was observed. No serious AE and no device-related AE were observed 
during the entire study period. The total number of AEs in the study was 20 (VCMX: 7; 
SCTG: 13). This predominantly encompassed gastrointestinal disorders, general 
infections and dizziness. 
 
Descriptive histology and histomorphometry 
Eighteen biopsies (VCMX=10; SCTG=8) could be harvested and 17 could be further 
processed for histologic analyses. Biopsies in group SCTG revealed a relatively loose 
network of collagen fibers with few inflammatory cells. No differentiation between 
transplanted connective tissue (CT) and newly formed CT was possible. In some 
specimens, bulks of adipocytes and few glandular cells were present. Vascularization was 
observed throughout the specimens with a relatively high number of smaller blood 
vessels (Figure 5A). In group VCMX, a dense collagen fiber network was present and the 
VCMX matrix could clearly be identified (Figure 5B). The matrix body, to some extent, 
revealed turn-over and remodeling processes. In some parts, the VCMX body was 
surrounded by a dense connective tissue, in other parts, by a looser network of newly 
formed collagen fibers. Thick elastic fibers were part of the VCMX body. Vascularization 
was present throughout the specimens. The number of inflammatory cells was limited. 
The histomorphometric assessment revealed a remaining matrix body of 32.1% 
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(±18.5%) and a mean amount of CT of 30.1% (±11.8%) (VCMX). In group SCTG, the 
mean amount of CT (transplanted and newly formed tissue) was 77.6% (±11.6%). The 
differences in CT was significant (p<0.05), but not the density of the harvested biopsies 
(background) (p>0.05).
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DISCUSSION 
The present RCT demonstrated that i) the soft tissue thickness increased up to 1.6mm 
with only minimal changes until the last follow-up without statistical differences between 
the groups; ii) soft tissue augmentation at implant sites was a safe procedure with a 
minimal number of complications using SCTG or VCMX; iii) PROMs, in general, favored 
the use of the VCMX and, iv) both, SCTG and VCMX integrated well into the surrounding 
soft tissues. 
With respect to the primary objective, the non-inferiority of VCMX could not be shown, 
since the study was underpowered for that specific analysis. This was due to the fact 
that the variability assumed in the sample size calculation was too low. However, the 
sample size was appropriate for describing the outcome variables and the respective 
changes. 
Various techniques and materials were suggested in the past to augment soft tissue 
volume prior to or simultaneous with implant placement, during the healing phase of the 
implant, at abutment connection or even after the insertion of the final reconstruction 
(Thoma et al., 2014b). Clinically, the timing and the decision on whether or not to 
augment depends on the clinician’s choice, the patient’s acceptance for the procedure 
and the clinical need (Levine et al., 2014). Even though a variety of materials including 
allogenic- and xenogenic materials were applied for that purpose, the use of the 
subepithelial connective tissue graft (SCTG) has been considered to be the gold 
standard (Thoma et al., 2014a). Clinical studies evaluating the increase in soft tissue 
volume following augmentation with SCTGs reported a range between 0.35-3.2mm 
depending on the location and follow-up time point (Thoma et al., 2014a, Eghbali et al., 
2014, De Bruyckere et al., 2015). In the present study the increase in soft tissue 
volume was assessed at three levels (on top of the implant, slightly buccal and more 
apical) and ranged between 0.56-1.56mm. Research activities in more recent years 
focused on the development of alternatives to replace autogenous soft tissues. This was 
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predominantly driven by a number of limitations and disadvantages associated with the 
use of autogenous tissue. Among these drawbacks, the donor site appears to be the 
critical issue resulting in an increased morbidity and a reduced patient’s acceptance for 
the procedure (Griffin et al., 2006, Zucchelli et al., 2010, Cairo et al., 2012, Harris et 
al., 2005, Del Pizzo et al., 2002). Only few clinical studies evaluated soft tissue 
substitutes for oral soft tissue volume augmentation. The obtained increase in soft 
tissue volume ranged between 0.35-2.14mm (Batista et al., 2001, Simion et al., 2012). 
The lack of longer-term data might in part be explained by a lack of performance of the 
tested soft tissue substitutes. The soft tissue substitute used in the present study has 
been successfully tested in a number of preclinical studies (Thoma et al., 2011, Thoma 
et al., 2010, Thoma et al., 2012b). Apart from favorable tissue integration, a soft tissue 
volume increase non-inferior to the SCTG was reported (Thoma et al., 2010). These 
results are supported by the present study. The obtained increase in soft tissue 
thickness was similar to the SCTG without statistically significant differences at any of 
the three measured sites. 
From a clinician’s and a patient’s perspective, a number of other parameters may play an 
important role in the decision-making process for using an autogenous soft tissue graft 
or a soft tissue substitute. This mainly involves PROMs (McGrath et al., 2012, Lang et 
al., 2012). Two kinds of questionnaires were used in the present study to evaluate 
PROMs: OHIP-14 and VAS scores. The OHIP-14 questionnaire is a short-form of the 
OHIP-49 assessing associations with socio-ethnographic and clinical oral status variables. 
This questionnaire demonstrated good reliability, validity and precision without 
significant differences compared to the OHIP-49 for dentate patients (Slade, 1997). The 
applicability of OHIP-14 to evaluate soft tissue grafting procedures has not been 
evaluated, however, and – indeed - the right skewed data indicate limited sensitivity for 
low severity of complaints. In the present study, the VAS scores during the first three 
days after surgery were slightly higher for the SCTG group compared to the VCMX group 
and a higher consumption of analgesics for the SCTG group. This was underlined with 
OHIP-14 data demonstrating 50% more physical pain for SCTG compared to VCMX at SR 
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and the greatest differences in change (SR vs. BL) for physical pain (1.1, p=0.112) and 
social disability (0.9, p=0.123). These data are in line with other studies reporting on the 
use of soft tissue substitutes compared to autogenous soft tissue grafts (Sanz et al., 
2009, Lorenzo et al., 2012). In these studies, more favorable PROMs were reported for 
soft tissue substitutes compared to the use of autogenous soft tissue grafts involving 
less overall pain and a reduced consumption of analgesics. In addition, the same studies 
reported less surgical time needed to perform the surgeries in the groups with soft tissue 
substitutes, explaining it with the lack of a second surgical site. In the present study, the 
surgical time needed to perform soft tissue volume augmentation was not statistically 
significantly different between the two groups. Even though, in the VCMX group, no 
second surgical site (donor site) was needed, a similar surgical time was calculated. This 
finding might be explain by the following reasons: i) the learning curve associated with a 
new device compared to a routinely performed procedure (SCTG), ii) the skills and 
experience of the surgeons and, iii) a negligible time needed for the harvesting 
procedure relative to the duration of the entire surgery. Only surgeons experienced in 
soft tissue grafting procedures performed the surgical interventions. The high level of 
clinical skills and the routine use of these interventions probably masked the effect and 
influence of the second surgical site on the surgical time. 
No serious adverse events (AEs) and no device-related AEs were observed in the 
present study demonstrating that both materials can safely be used for the applied 
intervention. The total number of AEs however revealed a higher number associated 
with the group SCTG (13 compared to 20 in group VCMX). These AEs predominantly 
included general infections and gastrointestinal disorders, which might also be attributed 
to the concomitant medication such as antibiotics. Clinically, the status of the wound 
closure revealed a higher number of dehiscences present at the day of suture removal 
translated into an ODDs ratio of 0.22. This higher rate of clinical complications may be 
due to the above-mentioned learning curve with the new soft tissue substitute 
(Chambers, 2012). The VCMX used in the present study, has not been tested in the 
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clinic before and the surgical technique was adapted from the routine procedure with 
SCTGs. This technique may not be ideal for the use of this new device and might have 
to be adapted to the new device in the future.  In contrast to SCTGs, the VCMX feature 
a high elasticity and are being soaked with blood immediately. Any pressure applied 
onto the device during surgery lead to an initial compression of the device, which within 
minutes reached the initial volume again. This elasticity is clearly in contrast to SCTGs 
(being relatively resistant to compression) and requires a completely tension-free 
wound closure. Even though, 33% of VCMX sites demonstrated a dehiscence at 7 days, 
the further healing was free of complications and complete wound closure was observed 
in all sites at 30 days. A complication-free healing following wound dehiscences and no 
signs of foreign body reactions with the applied cross-linked VCMX is in contrast to 
previous preclinical and clinical studies that demonstrated a high rate of wound 
dehiscences and subsequent infections using cross-linked devices (Becker et al., 2009, 
Annen et al., 2011).  
Histologic data provide a reliable instrument to analyze tissue integration and to assess 
the turn-over of implanted autogenous tissue and soft tissue substitutes (Ghanaati et 
al., 2011). The integration of autogenous tissue and VCMX into surrounding hard and 
soft tissues was evaluated in a recent preclinical study. The study reported a distinct 
border between the SCTG and the underlying bone and a tight integration towards the 
covering buccal flap without a clear distinction between augmented tissue and covering 
flap, whereas the bulk of the SCTG consisted of a dense connective tissue, adipocytes, 
glandular cells and blood vessels at 3 months. VCMX sites revealed an encapsulated and 
well-organized collagen matrix network infiltrated with newly formed connective tissue 
at 1 month. Two months later, tissue integration of VCMX had increased and remodeling 
processes and turn-over had taken place (Thoma et al., 2011). These data correlate 
with the findings of the present study. SCTG biopsies revealed a relatively loose 
connective tissue network reaching 78% of the volume, whereas VCMX sites consisted 
of almost identical amounts of remaining collagen matrix (32%) and newly formed 
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connective tissue (30%) with only few inflammatory cells present. This demonstrated 
that the newly developed VCMX integrated well into the surrounding soft tissues 
allowing remodeling processes and enhancing the formation of new connective tissue 
within the matrix body in way consistent with data from previous preclinical studies 
(Thoma et al., 2011, Thoma et al., 2012b). 
The present study was designed as a RCT to demonstrate non-inferiority. A power 
calculation was performed and based on the only data for VCMX that were available at 
the time of the protocol development (Thoma et al., 2011). Since no clinical data were 
available at that time, using a similar clinical protocol, interindividual patient differences 
and variations with respect to measured outcomes were underestimated. This resulted 
in a study design underpowered to demonstrate a non-inferiority model. Future studies 
can be designed using a power calculation based on the data of the present study These 
clinical trials will be needed to further assess soft tissue volume augmentation surgeries 
at implant sites and to demonstrate that VCMX can replace autogenous tissue for this 
type of intervention. Moreover, such clinical studies should focus on a longer-term 
follow-up similar to what has been reported for other soft tissue substitutes for root 
coverage procedures (Harris, 2004). 
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CONCLUSIONS 
The use of the three-dimensionally stable collagen matrix and the subepithelial 
connective tissue graft for soft tissue augmentation at implant sites rendered a similar 
gain in soft tissue volume. Only minimal changes in soft tissue thickness were observed 
between the first and last follow-up at 90 days. The surgical procedures using VCMX or 
SCTG were safe with only a minimal number of complications. Patient-reported outcome 
measures, slightly favored the use of VCMX without significant differences. The 
histological analysis revealed well-integrated grafts without foreign body reactions in 
both groups. The VCMX allowed remodeling processes and enhanced the formation of 
new connective tissue within the matrix body. Both, VCMX and SCTG can be effectively 
and safely used for the soft tissue augmentation at implant sites resulting in an increase 
in soft tissue volume up to 90 days based on this RCT. Clinical studies with a longer-
term follow-up, however, will be needed in the future to support these early short-term 
based findings. 
  25 
ACKNOWLEDGMENTS AND CONFLICTS OF INTEREST 
The present study was supported by Geistlich Pharma AG, Wolhusen, Switzerland, and 
by the Clinic of Fixed and Removable Prosthodontics and Dental Material Science, 
University of Zurich. The authors gratefully acknowledge the support of Gisela Müller, 
Clinic of Fixed and Removable Prosthodontics and Dental Material Science, University of 
Zurich, as well as support and expertise of Dr. Lorenz Uebersax (previously at Geistlich 
Pharma AG, Wolhusen, Switzerland) and Sibylle Huber, Geistlich Pharma AG, Wolhusen, 
Switzerland, during the study. The skilled of Sonja Hitz, Clinic of Fixed and Removable 
Prosthodontics and Dental Material Science, University of Zurich, for the preparation and 
analysis of the histologic samples is highly acknowledged. 
  26 
REFERENCES 
 
Aghaloo, T. L. & Moy, P. K. (2007) Which hard tissue augmentation techniques are the 
most successful in furnishing bony support for implant placement? International 
Journal of Oral and Maxillofacial Implants 22 Suppl, 49-70. 
Annen, B. M., Ramel, C. F., Hammerle, C. H. & Jung, R. E. (2011) Use of a new cross-
linked collagen membrane for the treatment of peri-implant dehiscence defects: a 
randomised controlled double-blinded clinical trial. European Journal of Oral 
Implantology 4, 87-100. 
Araujo, M. G. & Lindhe, J. (2009) Ridge alterations following tooth extraction with and 
without flap elevation: an experimental study in the dog. Clinical Oral Implants 
Research 20, 545-549. doi:10.1111/j.1600-0501.2008.01703.x. 
Batista, E. L., Jr., Batista, F. C. & Novaes, A. B., Jr. (2001) Management of soft tissue 
ridge deformities with acellular dermal matrix. Clinical approach and outcome 
after 6 months of treatment. Journal of Periodontology 72, 265-273. 
doi:10.1902/jop.2001.72.2.265. 
Becker, J., Al-Nawas, B., Klein, M. O., Schliephake, H., Terheyden, H. & Schwarz, F. 
(2009) Use of a new cross-linked collagen membrane for the treatment of 
dehiscence-type defects at titanium implants: a prospective, randomized-
controlled double-blinded clinical multicenter study. Clinical Oral Implants 
Research 20, 742-749. doi:10.1111/j.1600-0501.2008.01689.x. 
Benninger, B., Andrews, K. & Carter, W. (2012) Clinical measurements of hard palate 
and implications for subepithelial connective tissue grafts with suggestions for 
palatal nomenclature. Journal of Oral and Maxillofacial Surgery 70, 149-153. 
doi:10.1016/j.joms.2011.03.066. 
Cairo, F., Cortellini, P., Tonetti, M., Nieri, M., Mervelt, J., Cincinelli, S. & Pini-Prato, G. 
(2012) Coronally advanced flap with and without connective tissue graft for the 
treatment of single maxillary gingival recession with loss of inter-dental 
  27 
attachment. A randomized controlled clinical trial. Journal of Clinical 
Periodontology 39, 760-768. doi:10.1111/j.1600-051X.2012.01903.x. 
Chambers, D. (2012) Learning curves: what do dental students learn from repeated 
practice of clinical procedures? Journal of Dental Education 76, 291-302. 
Chiapasco, M., Casentini, P. & Zaniboni, M. (2009) Bone augmentation procedures in 
implant dentistry. International Journal of Oral and Maxillofacial Implants 24 
Suppl, 237-259. 
Cosyn, J., Pollaris, L., Van der Linden, F. & De Bruyn, H. (2015) Minimally-Invasive 
Single Implant Treatment (M.I.S.I.T.) based on ridge preservation and contour 
augmentation in patients with a high aesthetic risk profile: one-year results. 
Journal of Clinical Periodontology. doi:10.1111/jcpe.12384. 
De Bruyckere, T., Eghbali, A., Younes, F., De Bruyn, H. & Cosyn, J. (2015) Horizontal 
stability of connective tissue grafts at the buccal aspect of single implants: a 1-
year prospective case series. Journal of Clinical Periodontology 42, 876-882. 
doi:10.1111/jcpe.12448. 
Del Pizzo, M., Modica, F., Bethaz, N., Priotto, P. & Romagnoli, R. (2002) The connective 
tissue graft: a comparative clinical evaluation of wound healing at the palatal 
donor site. A preliminary study. Journal of Clinical Periodontology 29, 848-854. 
Eghbali, A., De Bruyn, H., Cosyn, J., Kerckaert, I. & Van Hoof, T. (2014) Ultrasonic 
Assessment of Mucosal Thickness around Implants: Validity, Reproducibility, and 
Stability of Connective Tissue Grafts at the Buccal Aspect. Clinical Implant 
Dentistry and Related Research. doi:10.1111/cid.12245. 
Esposito, M., Maghaireh, H., Grusovin, M. G., Ziounas, I. & Worthington, H. V. (2012) 
Soft tissue management for dental implants: what are the most effective 
techniques? A Cochrane systematic review. European Journal of Oral 
Implantology 5, 221-238. 
Fu, J. H., Hasso, D. G., Yeh, C. Y., Leong, D. J., Chan, H. L. & Wang, H. L. (2011) The 
accuracy of identifying the greater palatine neurovascular bundle: a cadaver 
study. Journal of Periodontology 82, 1000-1006. doi:10.1902/jop.2011.100619. 
  28 
Ghanaati, S., Schlee, M., Webber, M. J., Willershausen, I., Barbeck, M., Balic, E., 
Gorlach, C., Stupp, S. I., Sader, R. A. & Kirkpatrick, C. J. (2011) Evaluation of the 
tissue reaction to a new bilayered collagen matrix in vivo and its translation to 
the clinic. Biomedical materials 6, 015010. doi:10.1088/1748-6041/6/1/015010. 
Griffin, T. J., Cheung, W. S., Zavras, A. I. & Damoulis, P. D. (2006) Postoperative 
complications following gingival augmentation procedures. Journal of 
Periodontology 77, 2070-2079. doi:10.1902/jop.2006.050296. 
Harris, R. J. (2004) A short-term and long-term comparison of root coverage with an 
acellular dermal matrix and a subepithelial graft. Journal of Periodontology 75, 
734-743. doi:10.1902/jop.2004.75.5.734. 
Harris, R. J., Miller, R., Miller, L. H. & Harris, C. (2005) Complications with surgical 
procedures utilizing connective tissue grafts: a follow-up of 500 consecutively 
treated cases. International Journal of Periodontics and Restorative Dentistry 25, 
449-459. 
Jensen, S. S. & Terheyden, H. (2009) Bone augmentation procedures in localized defects 
in the alveolar ridge: clinical results with different bone grafts and bone-
substitute materials. International Journal of Oral and Maxillofacial Implants 24 
Suppl, 218-236. 
Kim, D. H., Won, S. Y., Bae, J. H., Jung, U. W., Park, D. S., Kim, H. J. & Hu, K. S. (2014) 
Topography of the greater palatine artery and the palatal vault for various types 
of periodontal plastic surgery. Clinical Anatomy 27, 578-584. 
doi:10.1002/ca.22252. 
Lang, N. P., Zitzmann, N. U. & Working Group 3 of the, V. E. W. o. P. (2012) Clinical 
research in implant dentistry: evaluation of implant-supported restorations, 
aesthetic and patient-reported outcomes. Journal of Clinical Periodontology 39 
Suppl 12, 133-138. doi:10.1111/j.1600-051X.2011.01842.x. 
Levine, R. A., Huynh-Ba, G. & Cochran, D. L. (2014) Soft tissue augmentation 
procedures for mucogingival defects in esthetic sites. International Journal of Oral 
  29 
and Maxillofacial Implants 29 Suppl, 155-185. 
doi:10.11607/jomi.2014suppl.g3.2. 
Lorenzo, R., Garcia, V., Orsini, M., Martin, C. & Sanz, M. (2012) Clinical efficacy of a 
xenogeneic collagen matrix in augmenting keratinized mucosa around implants: a 
randomized controlled prospective clinical trial. Clinical Oral Implants Research 
23, 316-324. doi:10.1111/j.1600-0501.2011.02260.x. 
Mathes, S. H., Wohlwend, L., Uebersax, L., von Mentlen, R., Thoma, D. S., Jung, R. E., 
Gorlach, C. & Graf-Hausner, U. (2010) A bioreactor test system to mimic the 
biological and mechanical environment of oral soft tissues and to evaluate 
substitutes for connective tissue grafts. Biotechnology and Bioengineering 107, 
1033-1043. doi:10.1002/bit.22893. 
McGrath, C., Lam, O. & Lang, N. (2012) An evidence-based review of patient-reported 
outcome measures in dental implant research among dentate subjects. Journal of 
Clinical Periodontology 39 Suppl 12, 193-201. doi:10.1111/j.1600-
051X.2011.01841.x. 
Milinkovic, I. & Cordaro, L. (2014) Are there specific indications for the different alveolar 
bone augmentation procedures for implant placement? A systematic review. 
International Journal of Oral and Maxillofacial Surgery 43, 606-625. 
doi:10.1016/j.ijom.2013.12.004. 
Prato, G. P., Cairo, F., Tinti, C., Cortellini, P., Muzzi, L. & Mancini, E. A. (2004) 
Prevention of alveolar ridge deformities and reconstruction of lost anatomy: a 
review of surgical approaches. International Journal of Periodontics and 
Restorative Dentistry 24, 434-445. 
Sanz, M., Lorenzo, R., Aranda, J. J., Martin, C. & Orsini, M. (2009) Clinical evaluation of 
a new collagen matrix (Mucograft prototype) to enhance the width of keratinized 
tissue in patients with fixed prosthetic restorations: a randomized prospective 
clinical trial. Journal of Clinical Periodontology 36, 868-876. doi:10.1111/j.1600-
051X.2009.01460.x. 
  30 
Schneider, D., Grunder, U., Ender, A., Hammerle, C. H. & Jung, R. E. (2011) Volume 
gain and stability of peri-implant tissue following bone and soft tissue 
augmentation: 1-year results from a prospective cohort study. Clinical Oral 
Implants Research 22, 28-37. doi:10.1111/j.1600-0501.2010.01987.x. 
Simion, M., Rocchietta, I., Fontana, F. & Dellavia, C. (2012) Evaluation of a resorbable 
collagen matrix infused with rhPDGF-BB in peri-implant soft tissue augmentation: 
a preliminary report with 3.5 years of observation. International Journal of 
Periodontics and Restorative Dentistry 32, 273-282. 
Slade, G. D. (1997) Derivation and validation of a short-form oral health impact profile. 
Community Dentistry and Oral Epidemiology 25, 284-290. 
Soileau, K. M. & Brannon, R. B. (2006) A histologic evaluation of various stages of 
palatal healing following subepithelial connective tissue grafting procedures: a 
comparison of eight cases. Journal of Periodontology 77, 1267-1273. 
Thoma, D. S., Benic, G. I., Zwahlen, M., Hammerle, C. H. & Jung, R. E. (2009) A 
systematic review assessing soft tissue augmentation techniques. Clinical Oral 
Implants Research 20 Suppl 4, 146-165. doi:10.1111/j.1600-
0501.2009.01784.x. 
Thoma, D. S., Buranawat, B., Hammerle, C. H., Held, U. & Jung, R. E. (2014a) Efficacy 
of soft tissue augmentation around dental implants and in partially edentulous 
areas: a systematic review. Journal of Clinical Periodontology 41 Suppl 15, S77-
91. doi:10.1111/jcpe.12220. 
Thoma, D. S., Hammerle, C. H., Cochran, D. L., Jones, A. A., Gorlach, C., Uebersax, L., 
Mathes, S., Graf-Hausner, U. & Jung, R. E. (2011) Soft tissue volume 
augmentation by the use of collagen-based matrices in the dog mandible -- a 
histological analysis. Journal of Clinical Periodontology 38, 1063-1070. 
doi:10.1111/j.1600-051X.2011.01786.x. 
Thoma, D. S., Jung, R. E., Schneider, D., Cochran, D. L., Ender, A., Jones, A. A., 
Gorlach, C., Uebersax, L., Graf-Hausner, U. & Hammerle, C. H. (2010) Soft tissue 
volume augmentation by the use of collagen-based matrices: a volumetric 
  31 
analysis. Journal of Clinical Periodontology 37, 659-666. doi:10.1111/j.1600-
051X.2010.01581.x. 
Thoma, D. S., Muhlemann, S. & Jung, R. E. (2014b) Critical soft-tissue dimensions with 
dental implants and treatment concepts. Periodontology 2000 66, 106-118. 
doi:10.1111/prd.12045. 
Thoma, D. S., Sancho-Puchades, M., Ettlin, D. A., Hammerle, C. H. & Jung, R. E. 
(2012a) Impact of a collagen matrix on early healing, aesthetics and patient 
morbidity in oral mucosal wounds - a randomized study in humans. Journal of 
Clinical Periodontology 39, 157-165. doi:10.1111/j.1600-051X.2011.01823.x. 
Thoma, D. S., Villar, C. C., Cochran, D. L., Hammerle, C. H. & Jung, R. E. (2012b) Tissue 
integration of collagen-based matrices: an experimental study in mice. Clinical 
Oral Implants Research 23, 1333-1339. doi:10.1111/j.1600-0501.2011.02356.x. 
Van der Weijden, F., Dell'Acqua, F. & Slot, D. E. (2009) Alveolar bone dimensional 
changes of post-extraction sockets in humans: a systematic review. Journal of 
Clinical Periodontology 36, 1048-1058. doi:10.1111/j.1600-051X.2009.01482.x. 
Vignoletti, F., Nunez, J. & Sanz, M. (2014) Soft tissue wound healing at teeth, dental 
implants and the edentulous ridge when using barrier membranes, growth and 
differentiation factors and soft tissue substitutes. Journal of Clinical 
Periodontology 41 Suppl 15, S23-35. doi:10.1111/jcpe.12191. 
Yu, S. K., Lee, M. H., Park, B. S., Jeon, Y. H., Chung, Y. Y. & Kim, H. J. (2014) 
Topographical relationship of the greater palatine artery and the palatal spine. 
Significance for periodontal surgery. Journal of Clinical Periodontology 41, 908-
913. doi:10.1111/jcpe.12288. 
Zucchelli, G., Mele, M., Stefanini, M., Mazzotti, C., Marzadori, M., Montebugnoli, L. & de 
Sanctis, M. (2010) Patient morbidity and root coverage outcome after 
subepithelial connective tissue and de-epithelialized grafts: a comparative 
randomized-controlled clinical trial. Journal of Clinical Periodontology 37, 728-
738. doi:10.1111/j.1600-051X.2010.01550.x. 
  32 
Zuhr, O., Baumer, D. & Hurzeler, M. (2014) The addition of soft tissue replacement 
grafts in plastic periodontal and implant surgery: critical elements in design and 
execution. Journal of Clinical Periodontology 41 Suppl 15, S123-142. 
doi:10.1111/jcpe.12185. 
  33 
FIGURE LEGENDS 
 
Figure 1: Flow-chart depicting visits, time-line and evaluated parameters. 
PROMs=patient-reported outcome measures. FU-30=follow-up at 30 days. FU-
90=follow-up at 90 days.  
Figure 2. Clinical procedures represented with one case (Collagen matrix). A. Clinical 
situation at screening. B. Prepared flap on top of ridge (full thickness) and on buccal side 
(split-thickness). C. Collagen matrix placed on top of the ridge and underneath the 
buccal flap. D. Primary wound closure. E. Suture removal at 7-10 days. F. Follow-up 
examination at 30 days (FU-30). G. Follow-up examination at 90 days (FU-90), roll flap 
to access dental implant. H. Healing abutment placed. I. Final reconstruction in situ (not 
part of the present study).  
Figure 3A: Virtual 3-D model of the individualized stent.  
Figure 3B: Individualized stent for transmucosal probing in situ. 
Figure 4A: Mean VAS scores for pain perceived by patients at different time-points 
including standard deviations. 
Figure 4B: Mean amount of analgesics (500mg tablets of mefenacid) consumption per 
day including standard deviations. 
Figure 5:  Histological section (Van Gieson-Elastica, x500 magnification).  A. 
SCTG=subepithelial connective tissue graft; B. VCMX= collagen matrix. VCMX=collagen 
matrix body. CT=connective tissue. EF=elastic fiber. BV=blood vessel. 
 
 
Table 1A: Patient demographics and p-values (Mann-Whintey test)SD=standard 
deviation. Q1=first quartile. Q3=third quartile. VCMX=collagen matrix. 
SCTG=subepithelial connective tissue grafts.  
Table 1B:  Location and number of augmented sites for each group. VCMX=collagen 
matrix. SCTG=subepithelial connective tissue grafts. 
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Table 2A: Mean baseline soft tissue thickness and p-values (Wilcoxon signed rank 
and Mann-Whitney test). SD=standard deviation. Q1=first quartile. Q3=third quartile. 
VCMX=collagen matrix. SCTG=subepithelial connective tissue grafts.  
Table 2B:  Change in soft tissue thickness and p-values (Wilcoxon signed rank and 
Mann-Whitney test). SD=standard deviation. Q1=first quartile. Q3=third quartile. 
VCMX=collagen matrix. SCTG=subepithelial connective tissue grafts. FU-30=Follow-up 
at 30 days. FU-90=Follow-up at 90 days. 
Table 3A: OHIP-14 domains and total scores: Descriptive statistics (number of cases 
(N), mean, standard deviation (SD), median, first (Q1) and third quartile (Q3)) of 
absolute values at baseline (top), sutural removal (=day 7) and at day 90 
Table 3B: OHIP-14 domains and total score: Descriptive statistics (number of cases 
(N), mean, standard deviation (SD), median, first (Q1) and third quartile (Q3)) changes 
at sutural removal (=day 7) vs. baseline (top) and changes at day 90 vs. sutural 
removal (bottom).  
Table 1A 
 
 
 
 
  VCMX 
(n=10) 
SCTG 
(n=10) 
p-value 
Gender n (female) 7 6 1.000 
n (male) 3 4  
Age Mean 43.8 42.7 1.000 
SD 13.2 19.1 
Median 45.0 46.7 
Q1 ; Q3 39.1 ; 47.8 22.4 ; 60.1 
p-value 0.002 0.002 
Cigarettes 
per day 
Mean 0.8 1.0 1.000 
SD 2.5 2.5 
Median 0.0 0.0 
Q1 ; Q3 0.0 ; 0.0 0.0 ; 0.0 
p-value 1.000 0.500 
 
 
 
 
 
  
 
 
Table 1B  
 
 
Site 15 14 13 12 11 21 22 23 24 25 
VCMX 1    3 2   1 3 
SCTG    2 2 4 1    
 
Site 45 44 43 42 41 31 32 33 34 35 
VCMX           
SCTG      1     
 
 
  
 
Table 2A  
 
  VCMX [mm] SCTG [mm] p-value 
Mucosal 
thickness of 
occlusal [mm] 
n 10 10 0.442 
Mean ± SD 3.4 ± 1.0 4.2 ± 1.9 
Median 3.5 3.8 
Q1 ; Q3 2.5 ; 4.0 3.0 ; 5.0 
p-value 0.002 0.002 
Mucosal 
thickness of 
buccal [mm] 
n 9 9 0.211 
Mean ± SD 2.9 ± 1.5 4.1 ± 2.0 
Median 3.0 4.0 
Q1 ; Q3 1.5 ; 4.0 3.5 ; 4.5 
p-value 0.004 0.004 
Mucosal 
thickness of 
apical [mm] 
n 10 9 0.246 
Mean ± SD 2.6 ± 2.3 3.4 ± 1.8 
Median 2.0 3.0 
Q1 ; Q3 1.0 ; 3.0 2.5 ; 3.5 
p-value 0.002 0.004 
 
 
 
 
  
Table 2B 
 
 
  VCMX [mm] SCTG [mm]  
  n Mean ± 
SD 
Median  
(Q1 ; Q3) 
p-value 
within 
group 
n Mean ± 
SD 
Median  
(Q1 ; Q3) 
p-value 
within 
group 
p-value 
between 
group 
Baseline 
to FU-30 
occlusal 10 0.9 ± 1.4 1.0 (0.0 ; 2.0) 0.090 10 0.9 ± 1.5 
0.5 
(0.0 ; 2.0) 0.156 0.987 
buccal 9 1.7 ± 1.6 1.0 (1.0 ; 3.0) 0.016 9 1.6 ± 2.3 
1.5 
(0.5 ; 2.5) 0.086 0.953 
apical 10 2.5 ± 1.6 2.5 (1.0 ; 4.0) 0.004 9 1.5 ± 2.6 
2.0 
(1.0 ; 3.0) 0.141 0.481 
Baseline 
to FU-90 
occlusal 10 1.4 ± 1.4 1.8 (0.5 ; 2.0) 0.018 10 0.8 ± 1.8 
0.5 
(-1.0 ; 2.0) 0.395 0.359 
buccal 9 1.1 ± 1.4 1.0 (0.5 ; 2.0) 0.074 7 0.8 ± 2.2 
1.5 
(-2.0 ; 2.0) 0.563 1.000 
apical 10 0.9 ± 1.9 0.0 (-0.5 ; 1.5) 0.281 8 1.6 ± 2.6 
1.8 
(-0.5 ; 3.3) 0.148 0.470 
FU-30 to 
FU-90 
occlusal 10 0.5 ± 1.9 0.3 (-0.5 ; 0.5) 0.730 10 -0.1 ± 1.4 
-0.5 
(-1.0 ; 1.0) 0.803 0.513 
buccal 10 -0.4 ± 1.4 -0.5 (-0.5 , 0.5) 0.492 8 -0.4 ± 2.0 
-0.3 
(-1.0 ; 0.8) 0.750 0.914 
apical 10 -1.7 ± 1.7 -1.5 (-3.0 ; 0.0) 0.016 9 0.6 ± 2.0 
1.0 
(0.0 ; 2.0) 0.398 0.015 
 
 
  
Table 3A 
 
 OHIP domains and total score: absolute values at baseline 
 
VCMX SCTG 
N Mean ± SD 
Median  
(Q1 ; Q3) 
N Mean ± SD 
Median  
(Q1 ; Q3) 
Functional limitation 10 0.6 ± 1.3 
0 
(0 ; 1) 10 
0.8 ± 0.8 
1 
(0 ; 1) 
Physical pain 10 1.0 ± 1.6 
0 
(0 ; 1) 10 
1.0 ± 1.1 
1 
(0 ; 2) 
Psychol. discomfort 10 1.2 ± 2.1 
0 
(0 ; 1) 10 
0.8 ± 1.3 
0 
(0 ; 1) 
Physical disability 10 0.3 ± 0.7 
0 
(0 ; 0) 10 
0.7 ± 1.2 
0 
(0 ; 2) 
Physiol. disability 10 1.2 ± 2.0 
0 
(0 ; 2) 10 
1.1 ± 1.3 
0.5 
(0 ; 2) 
Social disability 10 0.8 ± 1.6 
0 
(0 ; 1) 10 
0.2 ± 0.6 
0 
(0 ; 0) 
Handicap 10 0.5 ± 1.3 
0 
(0 ; 0) 10 
0.6 ± 1.0 
0 
(0 ; 1) 
Overall 10 5.6 ± 9.5 
2 
(1 ; 4) 10 
5.2 ± 6.1 
3 
(1 ; 9) 
 OHIP domains and total score: absolute values at SR 
 
VCMX SCTG 
N Mean ± SD 
Median  
(Q1 ; Q3) 
N Mean ± SD 
Median  
(Q1 ; Q3) 
Functional limitation 10 0.9 ± 1.4 
0 
(0 ; 1) 10 1.0 ± 1.2 
1 
(0 ; 1) 
Physical pain 10 1.5 ± 1.7 
1.5 
(0 ; 2) 10 2.6 ± 1.6 
3 
(1 ; 3) 
Psychol. discomfort 10 1.2 ± 1.7 
0.5 
(0 ; 2) 10 1.1 ± 1.5 
0.5 
(0 ; 2) 
Physical disability 10 0.5 ± 1.0 
0 
(0 ; 1) 10 0.5 ± 0.7 
0 
(0 ; 1) 
Physiol. disability 10 1.0 ± 1.5 
0 
(0 ; 2) 10 0.9 ± 1.1 
0.5 
(0 ; 2) 
Social disability 10 0.6 ± 1.3 
0 
(0 ; 0) 10 0.9 ± 1.9 
0 
(0 ; 1) 
Handicap 10 0.4 ± 1.0 
0 
(0 ; 0) 10 0.6 ± 1.1 
0 
(0 ; 1) 
Overall 10 6.1 ± 8.8 
3 
(0 ; 6) 10 7.6 ± 6.7 
5 
(3 ; 11) 
 OHIP domains and total score: absolute values at day 90 
 
VCMX SCTG 
N Mean ± SD 
Median  
(Q1 ; Q3) 
N Mean ±SD 
Median  
(Q1 ; Q3) 
Functional limitation 10 0.9 ± 1.3 
0 
(0 ; 2) 9 0.4 ± 0.9 
0 
(0 ; 0) 
Physical pain 10 0.7 ± 0.9 
0 
(0 ; 2) 8 1.1 ± 1.2 
1 
(0 ; 2) 
Psychol. discomfort 10 1.1± 1.3 
0.5 
(0 ; 2) 9 1.0 ± 1.1 
1 
(0 ; 2) 
Physical disability 10 0.3 ± 0.9 
0 
(0 ; 0) 9 0.7 ± 1.1 
0 
(0 ; 1) 
Physiol. disability 10 0.9 ± 1.4 
0 
(0 ; 2) 9 0.9 ± 1.2 
0 
(0 ; 2) 
Social disability 10 0.4 ± 1.0 
0 
(0 ; 0) 9 0.2 ± 0.7 
0 
(0 ; 0) 
 OHIP domains and total score: absolute values at baseline 
 
VCMX SCTG 
N Mean ± SD 
Median  
(Q1 ; Q3) 
N Mean ± SD 
Median  
(Q1 ; Q3) 
Handicap 10 0.3 ± 0.7 
0 
(0 ; 0) 9 0.7 ± 1.0 
0 
(0 ; 1) 
Overall 10 4.6 ± 5.9 
1.5 
(0 ; 8) 10 4.4 ± 5.6 
3 
(0 ; 7) 
 
 
Table 3B 
 
OHIP domains and total score: Change at SR vs. baseline 
 
VCMX SCTG 
N 
Mean 
(±SD) 
Median  
(Q1 ; Q3) 
N Mean (±SD) 
Median  
(Q1 ; Q3) 
Functional limitation 10 0.3 ± 1.1 
0 
(0 ; 0) 
10 0.2 ± 1.1 
0 
(-1 ; 1) 
Physical pain 10 0.5 ± 1.4 
0.5 
(0 ; 2) 
10 1.6 ± 1.6 
2 
(0 ; 3) 
Psychol. discomfort 10 0.0 ± 1.1 
0 
(-1 ; 1) 
10 0.3 ± 0.8 
0 
(0 ; 1) 
Physical disability 10 0.2 ± 0.4 
0 
(0 ; 0) 
10 -0.2 ± 1.2 
0 
(-1 ; 0) 
Physiol. disability 10 -0.2 ± 1.4 
0 
(-1 ; 0) 
10 -0.2 ± 1.2 
0 
(-1 ; 0) 
Social disability 10 -0.2 ± 1.1 
0 
(0 ; 0) 
10 0.7 ± 1.3 
0 
(0 ; 1) 
Handicap 10 -0.1 ± 0.3 
0 
(0 ; 0) 
10 0.0 ± 0.5 
0 
(0 ; 0) 
Overall 10 0.5 ± 3.1 
0.5 
(-1 ; 3) 
10 2.4 ± 5.0 
2 
(0 ; 4) 
OHIP domains and total score: Change at day 90 vs. SR 
 
VCMX SCTG 
N 
Mean 
(±SD) 
Median  
(Q1 ; Q3) 
N Mean (±SD) 
Median  
(Q1 ; Q3) 
Functional limitation 10 0.0 ± 0.8 
0 
(0 ; 0) 
9 -0.6 ± 1.1 
0 
(-1 ; 0) 
Physical pain 10 -0.8 ± 1.1 
0 
(-2 ; 0) 
8 -1.6 ± 2.0 
-1.5 
(-3 ; 0) 
Psychol. discomfort 10 -0.1 ± 1.3 
0 
(-1 ; 1) 
9 -0.2 ± 0.8 
0 
(0 ; 0) 
Physical disability 10 -0.2 ± 1.2 
0 
(0 ; 0) 
9 0.1 ± 1.2 
0 
(0 ; 1) 
Physiol. disability 10 -0.1 ± 0.9 
0 
(0 ; 0) 
9 -0.1 ± 0.8 
0 
(0 ; 0) 
Social disability 10 -0.2 ± 1.0 
0 
(0 ; 0) 
9 -0.8 ± 1.4 
0 
(-1 ; 0) 
Handicap 10 -0.1 ± 0.6 
0 
(0 ; 0) 
9 0.0 ± 0.7 
0 
(0 ; 0) 
Overall 10 -0.6 ± 4.1 
0 
(-2 ; 2) 
10 -1.3 ± 2.5 
-1.5 
(-3 ; 0) 
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